KZIA Kazia Therapeutics
- 0.288
- -0.001-0.48%
- 0.310
- +0.022+7.71%
Kazia Therapeutics News
Express News | Kazia Therapeutics Shares Are Trading Lower. The Company Announced the Completion of the EVT801 Phase 1 Clinical Trial
Express News | Kazia Reports Successful Stage 1 Completion of the EVT801 Phase 1 Clinical Trial in Advanced Cancer Patients
KAZIA REPORTS SUCCESSFUL STAGE 1 COMPLETION OF THE EVT801 PHASE 1 CLINICAL TRIAL IN ADVANCED CANCER PATIENTS
SYDNEY, May 1, 2024 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA), a biotechnology company specialising in oncology, is pleased to announce that the Safety Review Team (SRT) of the EVT801
Express News | Kazia Therapeutics Ltd Entered Into Purchase Agreement With Alumni Capital LP; Pursuant To Purchase Agreement, May Sell To Alumni Capital Up To $15M Of American Depositary Shares From Time To Time
Express News | Kazia Therapeutics Ltd - Pursuant to Purchase Agreement, May Sell to Alumni Capital up to $15 Mln of American Depositary Shares From Time to Time
Express News | Kazia Therapeutics Ltd - Entered Into Purchase Agreement With Alumni Capital LP
Why NextPlat Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket
Shares of NextPlat Corp (NASDAQ:NXPL) rose sharply in today's pre-market trading after the company reported consolidated 2023 revenues of $37.8 million, up 222% year over year NextPlat shares surged
Why Byrna Technologies Shares Are Trading Higher By Around 7%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Byrna Technologies Inc. (NASDAQ:BYRN) rose sharply during Friday's session after the company reported better-than-expected first-quarter revenue, and announced a CFO transition. Byrna Techno
Express News | Kazia Therapeutics Licenses Paxalisib To Sovargen For Intractable Seizures In Rare Central Nervous System Diseases
Express News | Kazia Presents Data At AACR Annual Meeting
Kazia Announces Presentation of New Data at AACR Annual Meeting
12 Health Care Stocks Moving In Friday's Pre-Market Session
GainersEnveric Biosciences (NASDAQ:ENVB) shares increased by 83.5% to $1.56 during Friday's pre-market session. The company's market cap stands at $4.2 million. Telesis Bio (NASDAQ:TBIO) stock increas
Kazia Therapeutics' Lead Drug Candidate Meets Goal of Early-Stage Study
Kazia Therapeutics (KZIA) on Wednesday said its lead drug candidate paxalisib met the primary goal of an early-stage clinical trial sooner than expected. The two-part phase 1 trial established the saf
What's Going With Australia-Based Cancer Firm Kazia Therapeutics On Wednesday?
Wednesday morning, Kazia Therapeutics Limited (NASDAQ:KZIA) announced the early conclusion based on safety and clinical response findings observed to date of an important two-part Phase 1 trial. Durin
12 Health Care Stocks Moving In Wednesday's Intraday Session
GainersEmergent BioSolutions (NYSE:EBS) stock increased by 77.0% to $2.69 during Wednesday's regular session. The market value of their outstanding shares is at $139.5 million. Ventyx Biosciences (NAS
Express News | Kazia Therapeutics Shares Are Trading Lower, After Initally Spiking Higher, Amid Increased Volatility in the Stock After the Company Announced the Early Conclusion of the Phase 1 Paxalisib Trial in Solid Tumors After Reaching the Primary Endpoint
Kazia Concludes Phase 1 Study for Paxalisib Early Due to Promising Data
Kazia Reports Positive Phase I Trial Results for Brain Cancer Therapy
Kazia Therapeutics Limited (NASDAQ: KZIA), an Australian biotechnology firm, has announced the early conclusion of a Phase I clinical trial due to positive safety and clinical response findings.
Express News | Kazia Therapeutics Shares Are Trading Higher After the Company Reported Early Conclusion of Phase 1 Paxalisib Trial in Solid Tumors After Reaching Primary Endpoint
Express News | Kazia Therapeutics Announced The Early Conclusion Based On Safety And Clinical Response Findings Observed To Date From A Two-part Phase 1 Trial Of Paxalisib With Radiation Therapy For PI3K Pathway Mutation Brain Metastases From Solid Tumors
Analysis
Price Target
No Data
